These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 9850444)
1. Development of Sang-35: a cyclosporine formulation bioequivalent to Neoral. First MR; Alloway R; Schroeder TJ Clin Transplant; 1998 Dec; 12(6):518-24. PubMed ID: 9850444 [TBL] [Abstract][Full Text] [Related]
2. Comparison of two cyclosporine formulations in healthy volunteers: bioequivalence of the new Sang-35 formulation and Neoral. Schroeder TJ; Cho MJ; Pollack GM; Floc'h R; Moran HB; Levy R; Moore LW; Pouletty P J Clin Pharmacol; 1998 Sep; 38(9):807-14. PubMed ID: 9753208 [TBL] [Abstract][Full Text] [Related]
3. How to convert from traditional cyclosporine to the microemulsion formulation in stable renal transplant patients? Gaspari F; Perico N; Pisoni R; Anedda MF; Signorini O; Caruso R; Gotti E; Remuzzi G Clin Transplant; 1998 Oct; 12(5):379-90. PubMed ID: 9787945 [TBL] [Abstract][Full Text] [Related]
4. Conversion of stable renal transplant recipients from Sandimmune to Sang-35, a Neoral-equivalent cyclosporine formulation, using a dose-adjusted method. First MR; Weiskittel P; Shah M; Peddi VR; Canafax D; Schroeder TJ Transplant Proc; 1998 Dec; 30(8):3955-7. PubMed ID: 9865260 [No Abstract] [Full Text] [Related]
5. Randomized, trough blood cyclosporine concentration-controlled trial to compare the pharmacodynamics of Sandimmune and Neoral in de novo lung transplant recipients. Trull A; Steel L; Sharples L; Stewart S; Parameshwar J; McNeil K; Wallwork J Ther Drug Monit; 1999 Feb; 21(1):17-26. PubMed ID: 10051050 [TBL] [Abstract][Full Text] [Related]
7. [A comparative randomized prospective multicenter study of Sandimmune vs Neoral in liver transplantation]. Roy A; Grant DR; Kneteman NM; Tchervenkov JI; Levy GA; Tan A; Hendricks L Ann Chir; 1998; 52(8):716-21. PubMed ID: 9846420 [TBL] [Abstract][Full Text] [Related]
9. Randomized, double-blind, one-year study of the safety and tolerability of cyclosporine microemulsion compared with conventional cyclosporine in renal transplant patients. International Sandimmun Neoral Study Group. Frei UA; Neumayer HH; Buchholz B; Niese D; Mueller EA Transplantation; 1998 Jun; 65(11):1455-60. PubMed ID: 9645802 [TBL] [Abstract][Full Text] [Related]
10. An open-label study of the safety and tolerability of converting stable liver transplant recipients to neoral. Pasha TM; Wiesner RH; Dahlke LM; Porayko MK; Krom RA Liver Transpl Surg; 1998 Sep; 4(5):410-5. PubMed ID: 9724479 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic, hemodynamic, and metabolic effects of cyclosporine sandimmune versus the microemulsion neoral in heart transplant recipients. White M; Pelletier GB; Tan A; Jesina C; Carrier M J Heart Lung Transplant; 1997 Aug; 16(8):787-94. PubMed ID: 9286770 [TBL] [Abstract][Full Text] [Related]
12. Sandimmune to Neoral conversion and value of abbreviated AUC monitoring in stable pediatric kidney transplant recipients. Kelles A; Herman J; Tjandra-Maga TB; Van Damme-Lombaerts R Pediatr Transplant; 1999 Nov; 3(4):282-7. PubMed ID: 10562972 [TBL] [Abstract][Full Text] [Related]
13. Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Mahalati K; Belitsky P; Sketris I; West K; Panek R Transplantation; 1999 Jul; 68(1):55-62. PubMed ID: 10428267 [TBL] [Abstract][Full Text] [Related]
14. A bioavailability study of cyclosporine: comparison of Neoral versus Cysporin in stable heart transplant recipients. Leet A; Richardson M; Senior JA; Funston R; Skiba M; Bailey M; Krum H J Heart Lung Transplant; 2009 Sep; 28(9):894-8. PubMed ID: 19716041 [TBL] [Abstract][Full Text] [Related]
15. Neoral use in the cardiac transplant recipient. Valantine H Transplant Proc; 2000 May; 32(3A Suppl):27S-44S. PubMed ID: 10814748 [TBL] [Abstract][Full Text] [Related]
16. Reduced intrapatient variability of cyclosporine pharmacokinetics in renal transplant recipients switched from oral Sandimmune to Neoral. Mendez R; Abboud H; Burdick J; Copley B; Freeman R; Batiuk TD; Cooney GF; Barbeito R Clin Ther; 1999 Jan; 21(1):160-71. PubMed ID: 10090433 [TBL] [Abstract][Full Text] [Related]
17. Bioequivalence of a new cyclosporine a formulation to Neoral. David-Neto E; Kakehashi E; Alves CF; Pereira LM; de Castro MC; de Mattos RM; Sumita NM; Romano P; Mendes ME; Nahas WC; Ianhez LE Ther Drug Monit; 2004 Feb; 26(1):53-7. PubMed ID: 14749551 [TBL] [Abstract][Full Text] [Related]
18. Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. International Neoral Renal Transplantation Study Group. Am J Transplant; 2002 Feb; 2(2):148-56. PubMed ID: 12099517 [TBL] [Abstract][Full Text] [Related]
19. Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy. Cantarovich M; Besner JG; Barkun JS; Elstein E; Loertscher R Clin Transplant; 1998 Jun; 12(3):243-9. PubMed ID: 9642517 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and tolerability of a microemulsion formulation of cyclosporine in renal allograft recipients--a concentration-controlled comparison with the commercial formulation. Mueller EA; Kovarik JM; van Bree JB; Lison AE; Kutz K Transplantation; 1994 Apr; 57(8):1178-82. PubMed ID: 8178343 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]